|
SkinBioTherapeuticsPLC on Thursday said it expects full year revenue below market forecasts as a result of order delays. The Newcastle Upon Tyne, England-based life science firm focused on skin health predicts revenue for the year ended June 30 between £4.5 million and £4.8 million. This is a near-fourfold increase from £1.2 million a year ago, but misses the £5.1 million company-cited consensus. ‘Revenues were slightly lower than market expectations due to timing of orders for Dermatonics and BTS, much of which occurred just after the year end,’ SkinBio noted. Adjusted Ebitda loss is estimated to range from £200,000 to £400,000, narrowed from a £2.2 million Ebitda loss in 2024. This is line with expectations for a loss around £300,000. SkinBio said its year-end cash position was better than expected, at £4.8 million as of June 30, up from £1.2 million at December 31, and slightly above the £4.1 million forecast. The cash boost was attributed to a June retail offer which grossed £4.2 million, intended to fund a tie-up with high street retailer Superdrug Stores PLC, which will be the exclusive seller of AxisBiotix supplements in UK stores. SkinBio retains worldwide rights for online sales and began incurring costs related to the Superdrug deal towards the end of financial 2025. The Superdrug roll-out on track to launch in autumn, and SkinBio noted that the new year had begun with ‘good trading across the board’ in July. SkinBio shares traded 0.7% higher at 14.10 pence on Friday afternoon in London, and have gained 9.5% in the past 12 months. Chief Executive Stuart Ashman said the Superdrug deal, alongside the launch of a supplement called Zenakine by subsidiary Croda Beauty, ‘have marked a distinct change in the operations of the company’. ‘Compared to where we were only five years ago, where our majority focus was around research and development, we have come a long way. We strongly believe that the increased interest by consumers and the marketplace in the role of the microbiome on our skin health means that we are very well placed to scale rapidly,’ the CEO added. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
